Laureate, Alopexx in MAb Mfg. Pact

Laureate Pharma, Inc. has entered into a contract manufacturing agreement with Alopexx Pharmaceuticals to produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and later for commercial production for the treatment and prevention of Staphylococcus aureus infections.  
   
“We are pleased that Alopexx chose Laureate Pharma as their manufacturing partner,” said Robert J. Broeze, Ph. D., president and chief executive officer of Laureate. “We will closely collaborate with the Alopexx team and help them drive their product from development into the clinic.”
   
“Laureate Pharma has a track record of demonstrated expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials,” said Dr. Daniel Vlock, president and chief executive officer of Alopexx. “We look forward to our partnership with Laureate and advancing our antibody therapeutics program into the clinic.”